Coadministration of trametinib and palbociclib radiosensitizes KRAS-mutant non-small cell lung cancers in vitro and in vivo

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 122-133

  Tao, Zhen ^a,b   Le Blanc, Justin M ^a   Wang, Chenguang ^c   Zhan, Tingting ^a   Zhuang, Hongqing ^b   Wang, Ping ^b   Yuan, Zhiyong ^b   Lu, Bo ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PALBOCICLIB; RETINOBLASTOMA BINDING PROTEIN; TRAMETINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RADIOSENSITIZING AGENT; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTS ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIZATION; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; RADIATION TOLERANCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DNA REPAIR; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; PYRIDONES; PYRIMIDINONES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RAS PROTEINS; RETINOBLASTOMA PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954485154     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0589     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Brunelli L, Caiola E, Marabese M, Broggini M, Pastorelli R. "Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget 2014;5:4722-31.
3. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22: 2616-410.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
6. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
7. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:0057-61.
8. Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Cur Op Pharm 2008;8:413-8.
9. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012;18:2316-25.
10. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:2450-7.
11. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
12. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. PNAS 2011;108:8773-8.
13. Watanabe M, Sowa Y, Yogosawa M, Sakai T. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci 2013; 104:687-93.
14. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. Ras oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-74.
15. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-19.
16. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 2009;8:834-43.
17. Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, et al. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther. 2010; 9:3351-62.
18. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-90.
19. Sebolt-Leopold JS, Herrera R. Targeting the mitogenactivated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
20. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F. Ras signaling and therapies. Adv Cancer Res 2009;102:1-17.
21. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26:2139-46.
22. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009;283:125-34.
23. Wee S, Jagani Z, Xiang X, Loo A, Dorsch M, Yao Y, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286.
24. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010;18:63-73.
25. Aktas H, Cai H, Cooper GM. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol 1997;17:3850-7.
26. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. Activation with favorable pharmacokinetic properties for GSK1120212 (JTP-74057) is an inhibitor of MEK activity and sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
27. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;25:2589-97.
28. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nature Med 2012;18:1503-10.
29. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
30. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
31. Ohtani N, Yamakoshi K, Takahashi A, Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 2004;51:146-53.
32. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220-7.
33. Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, et al. A high content clonogenic survival drug screen identifies MEK inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer. J Thorac Oncol 2014;9:965-73.
34. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-6.
35. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
36. Okumura S, Janne PA. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers. Clin Cancer Res 2014;20:4193-9.
37. Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, et al. Determination of synthetic lethal interactions in KRAS oncogenedependent cancer cells reveals novel therapeutic targeting strategies. Cell Res 2012;22:1227-45.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2010;100:57-70.
39. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.
40. Heist RS, Engelmen JA. SnapShot: non-small cell lung cancer. Cancer Cell 2012;3:448.
41. Yoshida T, Kakegawa J, Yamaguchi T, Hantani Y, Okajima N, Sakai T. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. Oncotarget 2012;3: 1533-45.
42. Zhang X, Cheng Y, Shin J, Kim J, Oh J, Kang J. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. Cancer Bio Ther 2013;14:597-605.
43. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, et al. Identification of common predictive markers of in vitro response to the mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010; 9:1985-94.
44. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 2010;16:1094-9.
45. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38.
46. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104:476-87.
47. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013;19:5320-8.
48. Mao CQ, Xiong MH, Liu Y, Shen S, Du XJ, et al. Synthetic Lethal Therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery. Mol Ther 2014;22:964-73.
49. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38.
50. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.